ZIVO CEO letter highlights algae antioxidant validation and animal health progress

Zivo Bioscience, Inc.

Independent analysis showed ZIVO's algae has nearly double SOD activity vs. a competing algae product.
Poultry avian influenza study: treated birds showed delayed transmission, lower viral shedding, faster immune response.
Management and board personally invested in the Company, signaling conviction in undervalued stock.
Company targets $4.5B antibiotic-free feed market growing at 8.2% CAGR through 2033.
CEO acknowledges liquidity challenges but expects near-term revenue from nutraceutical commitments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.